Drugs / CordIn
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02504619 | Apr → Aug 2016 | sickle cell disease, thalassemia | Gamida Cell ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CordIn | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02504619 ↗ |
| Modality | Cell therapy | “CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.” NCT02504619 ↗ |